Anti-LARG2/ LARGE2/ GYLTL1B functional antibody

Anti-LARG2/ LARGE2/ GYLTL1B functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to LARGE2/LARGE2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0252-Ab-1/ GM-Tg-hg-SE0252-Ab-2Anti-Human LARGE2 monoclonal antibodyHuman
GM-Tg-rg-SE0252-Ab-1/ GM-Tg-rg-SE0252-Ab-2Anti-Rat LARGE2 monoclonal antibodyRat
GM-Tg-mg-SE0252-Ab-1/ GM-Tg-mg-SE0252-Ab-2Anti-Mouse LARGE2 monoclonal antibodyMouse
GM-Tg-cynog-SE0252-Ab-1/ GM-Tg-cynog-SE0252-Ab-2Anti-Cynomolgus/ Rhesus macaque LARGE2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0252-Ab-1/ GM-Tg-felg-SE0252-Ab-2Anti-Feline LARGE2 monoclonal antibodyFeline
GM-Tg-cang-SE0252-Ab-1/ GM-Tg-cang-SE0252-Ab-2Anti-Canine LARGE2 monoclonal antibodyCanine
GM-Tg-bovg-SE0252-Ab-1/ GM-Tg-bovg-SE0252-Ab-2Anti-Bovine LARGE2 monoclonal antibodyBovine
GM-Tg-equg-SE0252-Ab-1/ GM-Tg-equg-SE0252-Ab-2Anti-Equine LARGE2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0252-Ab-1/ GM-Tg-hg-SE0252-Ab-2; GM-Tg-rg-SE0252-Ab-1/ GM-Tg-rg-SE0252-Ab-2;
GM-Tg-mg-SE0252-Ab-1/ GM-Tg-mg-SE0252-Ab-2; GM-Tg-cynog-SE0252-Ab-1/ GM-Tg-cynog-SE0252-Ab-2;
GM-Tg-felg-SE0252-Ab-1/ GM-Tg-felg-SE0252-Ab-2; GM-Tg-cang-SE0252-Ab-1/ GM-Tg-cang-SE0252-Ab-2;
GM-Tg-bovg-SE0252-Ab-1/ GM-Tg-bovg-SE0252-Ab-2; GM-Tg-equg-SE0252-Ab-1/ GM-Tg-equg-SE0252-Ab-2
Products NameAnti-LARGE2 monoclonal antibody
Formatmab
Target NameLARGE2
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LARGE2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0252-Ag-1Recombinant multi-species LARG2/ LARGE2/ GYLTL1B protein


    Target information

    Target IDGM-SE0252
    Target NameLARGE2
    Gene ID120071,228366,311202,714846,483638,101085315,510504,100056834
    Gene Symbol and Synonyms5730485C17Rik,GYLTL1B,LARGE2,Largel,mKIAA4105,PP5656
    Uniprot AccessionQ8N3Y3,Q6P7A1
    Uniprot Entry NameLARG2_HUMAN,LARG2_RAT
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000165905
    Target ClassificationN/A

    The target: LARGE2, gene name: LARGE2, also named as GYLTL1B, PP5656. Predicted to enable dystroglycan binding activity; glucuronosyltransferase activity; and xylosyltransferase activity. Involved in protein O-linked mannosylation. Predicted to be located in intracellular membrane-bounded organelle. Predicted to be active in Golgi apparatus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.